Key result
Soluble CD74 plus MIF cuts cardiac myofibroblast viability to ~48% by inducing necroptosis.
Absolute Event Rate: 47.9% vs 98.8%
p-value: p=<0.001
The synergistic interaction of sCD74 and MIF specifically induces necroptosis in cardiac myofibroblasts, suggesting this axis may be a promising therapeutic target for modulating cardiac remodeling and fibrosis post-myocardial infarction.
Background Although macrophage migration inhibitory factor ( MIF ) has been demonstrated to mediate cardioprotection in ischemia/reperfusion injury and antagonize fibrotic effects through its receptor, CD 74, the function of the soluble CD 74 receptor ectodomain ( sCD 74) and its interaction with circulating MIF have not been explored in cardiac disease. Methods and Results Cardiac fibroblasts were isolated from hearts of neonatal mice and differentiated into myofibroblasts. Co-treatment with recombinant MIF and sCD 74 induced cell death ( P<0.001), which was mediated by receptor-interacting serine/threonine-protein kinase ( RIP) 1/ RIP 3-dependent necroptosis ( P=0.0376). This effect was specific for cardiac fibroblasts and did not affect cardiomyocytes. Gene expression analyses using microarray and RT - qPCR technology revealed a 4-fold upregulation of several interferon-induced genes upon co-treatment of myofibroblasts with sCD 74 and MIF (Ifi44: P=0.011; Irg1: P=0.022; Clec4e: P=0.011). Furthermore, Western blot analysis confirmed the role of sCD 74 as a modulator of MIF signaling by diminishing MIF -mediated protein kinase B ( AKT) activation ( P=0.0197) and triggering p38 activation ( P=0.0641). We obtained evidence that sCD 74 inhibits MIF -mediated survival pathway through the C-X-C chemokine receptor 4/ AKT axis, enabling the induction of CD 74-dependent necroptotic processes in cardiac myofibroblasts. Preliminary clinical data revealed a lowered sCD 74/ MIF ratio in heart failure patients (17.47±10.09 versus 1.413±0.6244). Conclusions These findings suggest that treatment of cardiac myofibroblasts with sCD 74 and MIF induces necroptosis, offering new insights into the mechanism of myofibroblast depletion during scar maturation. Preliminary clinical data provided first evidence about a clinical relevance of the sCD 74/ MIF axis in heart failure, suggesting that these proteins may be a promising target to modulate cardiac remodeling and disease progression in heart failure.
No takes yet. Share an insight, caveat, or question.
Soppert et al. (2018) studied Heart failure and cardiac fibrosis (n=13). Soluble CD74 and macrophage migration inhibitory factor (MIF) vs. Untreated control or individual treatments was evaluated on Cell viability in cardiac myofibroblasts (p=<0.001). Co-treatment with soluble CD74 and macrophage migration inhibitory factor reduced viability of cardiac myofibroblasts to 47.9% compared to 98.8% with MIF alone by inducing necroptosis (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: